2,614 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Wallace Advisory Group LLC

Wallace Advisory Group LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,614 shares of the company’s stock, valued at approximately $171,000.

A number of other institutional investors have also bought and sold shares of the business. Stratos Wealth Advisors LLC lifted its position in shares of AstraZeneca by 2.0% during the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after purchasing an additional 133 shares in the last quarter. Crumly & Associates Inc. increased its stake in AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after buying an additional 143 shares during the period. Harbour Investments Inc. increased its stake in AstraZeneca by 1.9% during the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock worth $686,000 after buying an additional 160 shares during the period. Smith Salley Wealth Management boosted its position in AstraZeneca by 1.0% in the 3rd quarter. Smith Salley Wealth Management now owns 16,158 shares of the company’s stock valued at $1,259,000 after buying an additional 162 shares during the period. Finally, Veracity Capital LLC grew its stake in shares of AstraZeneca by 4.5% in the third quarter. Veracity Capital LLC now owns 3,833 shares of the company’s stock worth $299,000 after acquiring an additional 164 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Stock Performance

NASDAQ:AZN opened at $65.37 on Wednesday. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The firm has a market capitalization of $202.69 billion, a PE ratio of 31.28, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. The business’s fifty day moving average price is $65.98 and its 200 day moving average price is $74.69.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.87 EPS. On average, sell-side analysts anticipate that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AZN has been the topic of several analyst reports. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.